Nurix Therapeutics (NRIX) Depreciation & Amortization (CF) (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Depreciation & Amortization (CF) data on file, last reported at $2.3 million in Q2 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 0.58% year-over-year to $2.3 million in Q2 2026; TTM through May 2026 was $8.6 million, a 10.24% decrease from a year earlier, with the FY2025 full-year figure at $8.7 million, down 6.63% from the prior year.
• Depreciation & Amortization (CF) for Q2 2026 stood at $2.3 million, up from $2.2 million in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for NRIX reached as high as $2.5 million in Q4 2024 and fell as low as $991000.0 in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $2.0 million across 5 years, with a median of $2.0 million in 2024.
• Across the five-year window, Depreciation & Amortization (CF) jumped 116.67% in 2022 and slipped 18.4% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $1.6 million in 2022, then rose by 21.08% to $1.9 million in 2023, then surged by 34.09% to $2.5 million in 2024, then retreated by 18.4% to $2.1 million in 2025, then grew by 8.41% to $2.3 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $2.3 million in Q2 2026, $2.2 million in Q1 2026, and $2.1 million in Q4 2025.